Recent Company News

• 05:06 AM ET Apr 01, 2026
  

  Sihuan Pharma and Biocytogen signs strategic collaboration agreement to conduct innovative drug R&D (HK$1.45, 0.00)

• 12:05 AM ET Mar 31, 2026
  

  Sihuan Pharmaceutical Holdings Group reports FY net income attributable CNY179.7M vs year-ago (CNY216.7M) (HK$1.37, +0.03)

• 07:22 AM ET Mar 24, 2026
  

  Xuanzhu Biopharmaceutical provides final analysis results from phase 3 trial of bireociclib-fulvestrant combination for breast cancer (HK$37.60, 0.00)

• 03:29 PM ET Mar 22, 2026
  

  Xuanzhu Biopharmaceutical reports phase III clinical trial of Anaprazole Sodium Enteric-coated tablets completes enrollment (HK$43.00, 0.00)

• 10:09 PM ET Mar 05, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 03:47 AM ET Mar 03, 2026
  

  Xuanzhu Biopharmaceutical obtains NMPA marketing approval for new indication of Bireociclib Tablets (Xuanyuening) (HK$1.40, 0.00)

• 09:59 AM ET Feb 10, 2026
  

  Sihuan Pharmaceutical Holdings Group guides FY net income CNY150M vs FactSet CNY157.7M [3 est, CNY152-168M] (HK$1.67, 0.00)

• 09:43 PM ET Feb 04, 2026
  

  StreetAccount Summary - Hong Kong unusual volume traders

• 07:28 PM ET Feb 08, 2026
  

  Sihuan Pharmaceutical Holdings Group initiated buy at Sealand Securities (HK$1.64, 0.00)